Advancing the development of stem cell therapies for pets is the driving force behind a recently completed funding round.
Biotechnology company, Gallant Therapeutics, has announced the conclusion of its Series A financing, securing over $15 million. The financing round aims to enable Gallant to accelerate the development of its pipeline of allogeneic stem cell therapeutics, focusing on achieving the conditional U.S. Food and Drug Administration (FDA) approval of its therapeutic candidate targeting feline chronic gingivostomatitis (FCGS), a deadly disease with a high unmet medical need.
“We have made unprecedented progress this past year, hitting significant clinical, regulatory, and manufacturing milestones,” says Linda Black, DVM, Ph.D., CEO of Gallant Therapeutics. “This investment allows us to leverage our early-stage successes, extending beyond FCGS, to bring a diverse range of therapies to the broader pet market.”
Beyond FCGS, the company is also developing solutions that target osteoarthritis (OA), chronic kidney disease (CKD), and atopic dermatitis—all chronic diseases with a high burden of care in dogs and cats.